Alle Storys
Folgen
Keine Story von Sartorius AG mehr verpassen.

Sartorius AG

EANS-Adhoc: Sartorius AG
Preliminary Figures for Fiscal 2009

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
09.02.2010
Consolidated operating earnings up 7.2% | Strong operating cash flow 
| Substantial growth and overproportionate earnings increase in the 
Biotechnology Division | Slightly positive operating earnings in the 
Mechatronics Division due to extensive cost-cutting measures | Growth
in sales revenue and profit expected for both divisions in 2010
In fiscal 2009, the Sartorius Group received orders valued at 
615.1 million euros and thus 0.9% (currency-adjusted: -0.4%) more 
than in 2008 (609.8 mn. euros). Consolidated sales revenue is at 
602.1 million euros, and eased 1.6% (currency-adjusted:  -2.7%) from 
the year-earlier figure (611.6 mn. euros).
For the Biotechnology Division, order volume climbed 11.5% 
(currency-adjusted: +10.3%) to 409.2 million euros from 367.1 million
euros a year ago; sales revenue rose 9.4% (currency-adjusted: +8.3%) 
to 400.4 million euros from 366.0 million euros in 2008. By contrast,
the value of the orders posted by the Mechatronics Division slid 
15.2% (currency-adjusted: -16.6 %), because of the global recession, 
to 205.9 million euros from 242.7 million euros a year earlier; the 
division´s sales revenue fell 17.9% (currency-adjusted: -19.3%) to 
201.7 million euros from 245.6 million euros a year earlier.
Consolidated earnings before interest, taxes and amortization and 
adjusted for extraordinary expenses (underlying EBITA or operating 
earnings) rose 7.2% to 60.9 million euros, up from 56.8 million euros
a year ago; the respective margin, from 9.3% to 10.1%. The 
Biotechnology Division contributed 60.2 million euros (previous year 
39.7 mn. euros) to these earnings, and posted a significant margin 
increase from 10.9% to 15.0%. At 0.7 million euros (previous year 
17.1 mn. euros), the Mechatronics Division delivered slightly 
positive earnings as a result of the restructuring measures 
implemented.
Adjusted for extraordinary expenses and excluding the two non-cash 
items of amortization and interest, consolidated net profit after 
minority interest at 20.8 million euros is 14.2% higher than the 
year-earlier figure of 18.2 million euros; the respective earnings 
per share rose from 1.07 euros to 1.22 euros. Extraordinary expenses,
which essentially comprise provisions for the restructuring program 
in the Mechatronics Division, total 30.0 million euros. In 
particular, due to the significant restructuring charges in the 
Mechatronics Division the unadjusted consolidated net profit after 
minority interest amounts to -7.3 million euros (12.4 mn. euros).
Operating cash flow surged from 53.0 million euros to 143.4 million 
euros; the ratio of net debt to underlying EBITDA improved to 2.6 as 
of December 31, 2009, from 2.7 a year ago.
For 2010, management expects currency-adjusted sales growth for the 
Biotechnology Division to reach the upper single-digit percentage 
range and the division´s operating EBITA margin to increase slightly.
For the Mechatronics Division, the company assumes that there will be
a slight upturn in the economy and, on this basis, anticipates 
currency-adjusted sales growth in the lower single-digit percentage 
range. Given the division´s considerably reduced cost base, 
Mechatronics is forecasted to achieve an operating EBITA margin of 
around 5%. For the Group as a whole, currency-adjusted sales revenue 
growth is likely to be slightly above 5% and its operating EBITA 
margin is expected to further improve by one to two percentage 
points. Moreover, management anticipates significantly positive 
operating cash flow.
The numbers given above are subject to final review by the auditors. 
The final figures will be released at the annual press conference on 
March 9, 2010.
Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius,
will discuss the results with analysts and investors on Wednesday, 
February 10, 2010, at 4:00 p.m. Central European Time (CET) in a 
teleconference. You may dial into the teleconference starting at 3:45
p.m. CET at the following numbers: Germany +49 (0)69 2222 2244; 
France +33 (0)1 70 99 42 74; UK +44 (0)20 7136 2053; USA +1 212 444 
0481 The dial-in code is: 8415130.
The webcast and presentation can be viewed at www.sartorius.com.
Goettingen, February 9, 2010
Sartorius AG
37070 Göttingen
Andreas Wiederhold
Phone +49(0)551.308.1668
Fax +49(0)551.308.3153
andreas.wiederhold@
sartorius.com
www.sartorius.com
|Ad hoc Announcement                |[pic]                           
|
end of announcement                               euro adhoc

Further inquiry note:

Henriette Meyer
Treasury & Investor Relations
Tel.: +49 (0)551-308-3232
E-Mail: henriette.meyer@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Weitere Storys: Sartorius AG
Weitere Storys: Sartorius AG